1. Home
  2. EVGOW vs CMMB Comparison

EVGOW vs CMMB Comparison

Compare EVGOW & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGOW

EVgo Inc.

HOLD

Current Price

$0.01

Market Cap

0.0

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.52

Market Cap

13.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVGOW
CMMB
Founded
2010
2004
Country
United States
Israel
Employees
376
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
13.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
EVGOW
CMMB
Price
$0.01
$1.52
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
365.6K
49.9K
Earning Date
03-07-2025
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
$239,306,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$38.00
Revenue Growth
73.08
N/A
52 Week Low
$0.00
$0.87
52 Week High
$0.27
$3.86

Technical Indicators

Market Signals
Indicator
EVGOW
CMMB
Relative Strength Index (RSI) 39.19 39.66
Support Level N/A $1.48
Resistance Level $0.03 $1.89
Average True Range (ATR) 0.01 0.17
MACD -0.00 -0.04
Stochastic Oscillator 3.83 4.60

Price Performance

Historical Comparison
EVGOW
CMMB

About EVGOW EVgo Inc.

EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Share on Social Networks: